Table 3.
Recommedation for therapy in patients with genotypes 2 and 3
| Patient characterization | Recommended | Duration (wk) | Scientific evidence |
| Genotype 2 naive noncirrhotic/cirrhotic | SOF + RBV | 12 | Fission positron |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| Genotype 2 retretated noncirrhotic | SOF + RBV | 12 | Fussion valence |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| Genotype 2 retreated cirrhotic | SOF + PEG + RBV | 12 | Lonestar-2 |
| SOF + RBV | 16 | Fussion valence | |
| Genotype 3 naive and retreated noncirrhotic/cirrhotic | SOF + RBV | 24 | Valence |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| SOF + LDV + RBV | 12 | Electron-2 | |
| SOF + DVC (No en cirróticos) | 12 | Ally-3 |